目录产品 » Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine)
Manual
SDS
COAs

Envelope glycoprotein E, His, Varicella-zoster virus (strain Oka vaccine)

VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen.
￥2600
Z06450

产品简介
Species Varicella-zoster virus (strain Oka vaccine)
Protein Construction
Envelope glycoprotein E (Ser31-Tyr538)
Accession # Q9J3M8		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC 
Endotoxin Level Less than 1 EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 58.39 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-85 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background VZV glycoprotein E (gE) is most abundantly expressed on the surface of infected cells, and is an essential component for virus replication and cell-to-cell transmission. It is also the main target of virus-specific antibodies and T cell responses that is often selected as vaccine candidate antigen.
Synonyms Envelope glycoprotein E; gE; ORF68;
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.